Disturbed cholesterol homeostasis plays critical roles in the development of multiple
diseases, such as cardiovascular diseases (CVD), neurodegenerative diseases and …

Non-alcoholic fatty liver DISEASE (NAFLD) is the most common chronic liver disease in
Western countries and affects approximately 25% of the adult population. Since NAFLD is …

Gut microbiota dysbiosis has been repeatedly observed in obesity and type 2 diabetes
mellitus, two metabolic diseases strongly intertwined with non-alcoholic fatty liver disease …

Importance Nonalcoholic steatohepatitis (NASH) is the inflammatory subtype of nonalcoholic
fatty liver disease (NAFLD) and is associated with disease progression, development of …

Aims To objectively appraise evidence for possible adverse effects of long-term statin
therapy on glucose homeostasis, cognitive, renal and hepatic function, and risk for …

Non-alcoholic fatty liver (NAFLD) is the most common liver disease worldwide, progressing
from simple steatosis to necroinflammation and fibrosis (leading to non-alcoholic …

Given the high prevalence and rising incidence of non-alcoholic fatty liver disease (NAFLD),
the absence of approved therapies is striking. Although the mainstay of treatment of NAFLD …

The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing rapidly worldwide
as the obese and diabetic populations increase, and it has been estimated to be 20–30% in …

Background & Aims Patients with non-alcoholic fatty liver disease (NAFLD) are at increased
chance for cardiovascular events (CVEs). Severity of liver fibrosis is used to determine …

The hallmark of non‐alcoholic fatty liver disease (NAFLD) is excessive fatty accumulation in
the hepatocytes, which may be an isolated event (non‐alcoholic fatty liver, NAFL) or …